Document is current
Any future updates will be listed below
-
Authors
Zhu, Liyuan
Nguyen, Long T.
Bell, Alexandra G. https://orcid.org/0009-0001-2036-0455
Krebel, Tom https://orcid.org/0009-0001-9222-8453
Gillmann, Kara M.
Cao, Qinhao
Oatman, Harrison https://orcid.org/0000-0002-2699-6374
Hariri, Jack
Möglich, Andreas https://orcid.org/0000-0002-7382-2772
Myhrvold, Cameron https://orcid.org/0000-0002-8971-184X
Toettcher, Jared E. https://orcid.org/0000-0002-1546-4030
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM144362)
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 15 May 2026
First Online: 3 June 2026
Competing interests
: J.E.T. is a scientific advisor for Prolific Machines and Nereid Therapeutics. L.Z., L.T.N., C.M., and J.E.T. have submitted a provisional patent application on allosterically controlled Cas13d variants (US Patent Application No. 63/785,347). The remaining authors declare no competing interests.
